Skip to content
Screener

Supernus Pharmaceuticals SUPN Business Segments — Total revenues

Similar metrics at other companies

nCino, Inc. logo
NCNOReportable Segment — Total revenues
$159.41M+10.6%
BJ's Wholesale Club Holdings, Inc. logo
BJReportable Segment — Total revenues
$5.66B+9.9%
Calix logo
CALXReportable Segment — Total revenues
$293.33M+21.3%
CuriosityStream logo
CURIReportable Segment — Total revenues
$15.16M+0.5%
comScore logo
SCORReportable Segment — Total revenues
$85.32M-0.5%
Neurocrine Biosciences logo
NBIXReportable Segment — Total revenues
$814.5M+42.2%

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.72B+14.3%
Enterprise value$2.57B+13.6%
P/S3.5×-0.1×

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0.0×
Current ratio-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001356576-26-000022
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Total revenues$207,705$149,824
Less: Significant segment expenses:
Cost of revenues23,39115,763
Selling expenses66,27842,614
Marketing expenses20,69720,664
General and administrative expenses38,19826,666
Research and development expenses
External development program expenses:

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Supernus Pharmaceuticals's business segments — total revenues?
Supernus Pharmaceuticals (SUPN) reported business segments — total revenues of $207.71M in Q1 2026.
How has Supernus Pharmaceuticals's business segments — total revenues changed year-over-year?
Supernus Pharmaceuticals's business segments — total revenues increased by 38.6% year-over-year, from $149.82M to $207.71M.
What is the long-term trend for Supernus Pharmaceuticals's business segments — total revenues?
Over 3 years (2022 to 2025), Supernus Pharmaceuticals's business segments — total revenues has grown at a 2.5% compound annual growth rate (CAGR), from $667.24M to $718.95M.
What does business segments — total revenues mean?
Represents the total gross income generated by the company's primary business segment from the sale of pharmaceutical products. This metric serves as the top-line indicator of market demand and commercial success for the company's neuroscience portfolio.

Ask your AI about Supernus Pharmaceuticals's business segments — total revenues.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude